3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
145
Breast Neoplasms
113
Prostatic Neoplasms
58
Multiple Myeloma
57
Neoplasms
54
Lung Neoplasms
46
Neoplasm Metastasis
42
Ovarian Neoplasms
36
Parkinson Disease 4, Autosomal Dominant Lewy Body
34
Leukemia, Lymphocytic, Chronic, B-Cell
33
Colorectal Neoplasms
32
Carcinoma, Renal Cell
26
Recurrence
25
Leukemia, Myeloid, Acute
25
Urinary Bladder Neoplasms
23
Myasthenia Gravis
23
Carcinoma, Hepatocellular
23
Triple Negative Breast Neoplasms
21
Lymphoma, Large B-Cell, Diffuse
21
Squamous Cell Carcinoma of Head and Neck
20
Small Cell Lung Carcinoma
20
Lymphoma, Follicular
18
Fallopian Tube Neoplasms
18
Endometrial Neoplasms
18
Stomach Neoplasms
17
Nasopharyngeal Carcinoma
17
Melanoma
17
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Pancreatic Neoplasms
15
Non-Muscle Invasive Bladder Neoplasms
15
Interventions
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Muscle-invasive Bladder Cancer
×
90 days
×
Clear all
NCT04660344
2026-03-27
IMvigor011
Hoffmann-La Roche
Phase 3
Active not recruiting
761 enrolled
1 FDA